Influence of perindopril therapy on cardiovascular benefits in the Czech Republic

Česká verzia

Authors: Suchopár J.
Authors place of work: DrugAgency, a. s., Praha
Published in the journal: Kardiol Rev Int Med 2018, 20(4): 312-317

Summary

Perindopril belongs to the group of cardiovascular drugs and has the best documented efficacy and safety. Data from a number of randomised, controlled, multicentre and sufficiently robust studies clearly demonstrate a reduction in mortality and morbidity in patients treated with perindopril or its combination with indapamide or amlodipine. The Czech Republic is the world's leading consumer of perindopril (and ACE inhibitors in general). The consumption of perindopril over the last four years corresponds to treatment of more than 700,000 patients. The use of perindopril in common clinical practice in the Czech Republic reduces mortality and morbidity. From the calculations made, it can be deduced that the administration of perindopril is very likely to have prevented more than 6,000 deaths in the Czech Republic in the last four years.

Key words:

perindopril – ACE-inhibitors – drug consumption – mortality – morbidity

Zdroje

1. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358 (9287): 1033–1041. doi: 10.1016/ S0140-6736(01)06178-5.

2. Fox KM. EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362(9386): 782–788.

3. Špinar J, Vítovec J. Perindoprilum. Remedia 2005; 15(2): 121–135.

4. Patel A, MacMahon S, Chalmers J et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370(9590): 829–840.

5. Zoungas S, Chalmers J, Neal B et al. ADVANCE-ON Collaborative Group. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med 2014; 371(15): 1392–3406. doi: 10.1056/ NEJMoa1407963.

6. Teplan V. Vliv poklesu krevního tlaku a kontroly glykemie u pacientů s diabetem 2. typu: šestileté sledování po ukončení studie ADVANCE (studie ADVANCE ON). Interní Med 2014; 16(6): 222–226.

7. Dahlöf B, Sever PS, Poulter NR et al. ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366(9489): 895–906.

8. Cleland JG, Tendera M, Adamus J et al. PEP-CHF Investigators. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006; 27(19): 2338–2345. doi: 10.1093/ eurheartj/ ehl250.

9. Ferrari R. Perindopril and Remodeling in Elderly with Acute Myocardial Infarction Investigators: Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study. Arch Intern Med 2006; 166(6): 659–666. doi: 10.1001/ archinte.166.6.659.

10. Beckett NS, Peters R, Fletcher AE et al. HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358(18): 1887–1898. doi: 10.1056/ NEJMoa0801369.

11. Pilote L, Abrahamowicz M, Rodrigues E et al. Mortality rates in elderly patients who take different angiotensin-converting enzyme inhibitors after acute myocardial infarction: a class effect? Ann Intern Med 2004; 141(2): 102–112.

12. Pilote L, Abrahamowicz M, Eisenberg M et al. Effect of different angiotensin-converting-enzyme inhibitors on mortality among elderly patients with congestive heart failure. CMAJ 2008; 178(6): 1303–1311. doi: 10.1503/ cmaj.060068.

13. Brugts JJ, Ninomiya T, Boersma E et al. The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials. Eur Heart J 2009; 30(11): 1385–1394. doi: 10.1093/ eurheartj/ ehp103.

14. Liakos CI, Papadopoulos DP, Kotsis VT. Adherence to treatment, safety, tolerance, and effectiveness of perindopril/ amlodipine fixed-dose combination in greek patients with hypertension and stable coronary artery disease: a pan-hellenic prospective observational study of daily clinical practice. Am J Cardiovasc Drugs 2017; 17(5): 391–398. doi: 10.1007/ s40256-017-0232-5.

15. Simonyi G, Ferenci T, Medvegy M et al. One year persistence of free and fixed dose combinations of perindopril/ amlodipine. Orv Hetil 2017; 158(36): 1421–1425. doi: 10.1556/ 650.2017.30851.

16. Vytřísalová M. Adherence k medikamentózní léčbě – známa neznámá. Remedia 2009; 19(3): 225–230.

17. Srivastava K, Arora A, Kataria A et al. Impact of reducing dosing frequency on adherence to oral therapies: a literature review and meta-analysis. Patient Prefer Adherence 2013; 7: 419–434. doi: 10.2147/ PPA.S44646.

18. Moise N, Schwartz J, Bring R et al. Antihypertensive drug class and adherence: an electronic monitoring study. Am J Hypertens 2015; 28(6): 717–721. doi: 10.1093/ ajh/ hpu199.

19. Aznar-Lou I, Fernández A, Gil-Girbau M et al. Initial medication non-adherence: prevalence and predictive factors in a cohort of 1.6 million primary care patients. Br J Clin Pharmacol 2017; 83(6): 1328–1340. doi: 10.1111/ bcp.13215.

20. Qvarnström M, Kahan T, Kieler H et al. Persistence to antihypertensive drug classes. A cohort study using the Swedish Primary Care Cardiovascular Database (SPCCD). Medicine (Baltimore) 2016; 95(40): e4908. doi: 10.1097/ MD.0000000000004908.

21. Choi KH, Yu YM, Ah YM et al. Persistence with antihypertensives in uncomplicated treatment-naïve very elderly patients: a nationwide population-based study. BMC Cardiovasc Disord 2017; 17(1): 232. doi: 10.1186/ s12872-017-0665-4.

22. Spotřeby ACEI v ČR (2010–2017). Dostupné na: www.sukl.cz.

23. Žižka J, Souček M. Evaluation of cardiovascular high risk population in specialist ambulatory care: ESA. Vnitr Lek 2010; 56(5): 376–381.